:

Ioannis Ntanasis-Stathopoulos1, Ilias Katsadouros1, Panagiotis Malandrakis1

  • 1Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Oncology letters
|August 22, 2025
PubMed
概括

在治疗复发性/ 耐药性多发性骨髓瘤方面,Teclistamab 显示出有效性,即使是在患有严重脏疾病的患者中也是如此. 这种双特异性抗体导致末期病患者的疾病缓解和功能改善.